Sjögren's syndrome: shedding light on emerging and key drug targets. (3rd October 2022)

• Record Type: Journal Article
• Authors: Ridgewell, Dominic; Thalayasingam, Nishanthi; Ng, Wan-Fai
• Is Part Of: Expert opinion on therapeutic targets. Volume 26:Number 10(2022)
• Page Start: 869
• Page End: 882
• Publication Date: 2022-10-03
• Subjects: Sjögren's syndrome -- biologics -- clinical trials -- composite outcome measures -- ESSDAI; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2022.2157259
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction: Sjögren's syndrome (SS) is an immune-mediated inflammatory condition characterized by sicca syndrome, musculoskeletal pain, and fatigue. Extra-glandular manifestations are common and there is a markedly increased risk of lymphoma development. SS is associated with high health-economic burden driven largely by the symptom burden on patients. Currently, there is no approved disease-modifying treatment and management is based on empirical evidence. Progress in the understanding of SS pathogenesis has led to an expanding portfolio of more targeted therapies under development. Areas covered: This review summarizes the key development in targeted biological therapies in SS including emerging targets. It also highlights the challenges in therapeutic development in SS such as disease heterogeneity and defining appropriate disease assessment tools to evaluate therapeutic efficacy. Expert opinion: Early trials in SS failed to meet their primary outcomes which may in part due to the use of inappropriate or insensitive study endpoints. Recent trials targeting B-cells, B-T cell co-stimulation and IFN signaling have shown promising results. Development of composite endpoints including patient reported outcomes and objective disease measure may provide a more holistic approach to disease assessment. The impact of these new tools on therapeutic development that benefit patients remains to be fully evaluated.